Skip to content
FIND A HEALTH VALLEY ACTOR

The Biopôle Review – 2023 edition

Biopole review 2023

Check out all the key figures from Biopôle’s community, inspiring interviews and more in their latest review.     Biopôle, the life sciences campus based in Lausanne, brings together a strong community of industry and academia. It offers a world-class combination of infrastructure, added value services, living space and community engagement where partners can thrive…

Read More

Atinary and Takeda collaborate to drive innovation in healthcare

Atinary-takeda-partnership

Atinary Technologies, a Vaud based startup, announced a strategic collaboration with Takeda, Japanese largest pharmaceutical company.     This partnership brings together the two company’s complementary expertise, paving the way for innovative AI solutions poised to transform pharmaceutical R&D and accelerate drug discovery. Through this collaboration, Takeda will leverage Atinary’s leading AI Self-Driving Labs technology,…

Read More

Innovative materials to combat bacteria

UNIGE-innovative materials-bacteria

A UNIGE team is developing new alloys with bactericidal properties to combat antibiotic-resistant germs.     While crucial to biotechnology, bacteria can also cause severe disease, exacerbated by their increasing resistance to antibiotics. This duality between economic benefits and infectious risks underlines the importance of finding ways to control their development. A team at the…

Read More

Alys Pharmaceuticals launches with $100 Million financing from Medicxi

Alys Pharmaceuticals

Formed through the aggregation of six-asset centric Medicxi companies, including Aldena Therapeutics, Alys boasts a robust R&D pipeline of cutting-edge programmes and platforms targeting multiple dermatological indications.     Co-founded by Medicxi and several world-leading dermatology and scientific experts, Alys is a Boston and Geneva-based cutting edge pure-play immuno-dermatology company. It combines the assets and…

Read More

CHF 870 Million invested in Swiss medtech and biotech companies

Swiss Venture Capital Report

In the midst of an unfavourable environment, the life sciences’ sector continues to attract investors in Switzerland according to the Swiss Venture Capital Report 2024.     In 2023, the downturn on the global venture capital market reached Switzerland. Swiss startups received a total of CHF 2.6 Billion last year, 35% less than in 2022.…

Read More

FONGIT Life Sciences Café+Croissant

FONGIt cafe croissant August

The next FONGIT Café+Croissant is taking place on 18 September 2025 at Campus Biotech Geneva.   This monthly event brings together the entire FONGIT team and leading entrepreneurs from the local life sciences innovation community. Come find out what’s been going on in the Geneva life sciences startup scene, hear from entrepreneurs themselves, and expand…

Read More

First-in-Human implantation for Novostia’s heart valve

Novostia_implantation

The Vaud-based startup, located at the Biopôle, successfully implanted its TRIFLO valve in a human.     Novostia, a pioneering medical technology company, proudly announces a significant milestone in its mission to revolutionize cardiovascular care. Last December, the company has successfully implanted its groundbreaking TRIFLO Heart Valve in a human patient for the first time.…

Read More

Debiopharm Innovation Fund invests in MedaSystems

Debiopharm-innovation-fund

MedaSystems secures additional funding from Debiopharm Innovation Fund to accelerate global access to pre-approval treatment.     Medasystems, a pioneer in software to provide access to pre-approval medicine, announced funding from Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, motivated by their vision of patient centric, data-enabled clinical research and enabling…

Read More

Cellestia secures a CHF 2 Million grant from Innosuisse

Cellestia-innosuisse-grant-2

The Biopôle based startup was awarded an Innosuisse Grant to advance a groundbreaking Graft versus Host Disease prevention therapy.     Cellestia Biotech AG (Cellestia) announced its selection for a CHF 2 million grant from the Swiss Innovation Agency, Innosuisse, as part of their Startup Innovation project to advance to clinical Proof of Concept, a…

Read More

Advanced Therapies Congress

Advanced Therapies

The Advanced Therapies Congress is taking place on 17-18 March 2026 in London.   The Advanced Therapies Congress is Europe’s largest cell and gene therapy conference and exhibition. The event brings together the world leaders in ATMP (Advanced Therapy Medicinal Products) development and the most senior executives in charge of the latest tech and strategies.…

Read More